日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study

一项研究者发起的 II 期研究的最终报告:伊布替尼治疗伴或不伴 TP53 异常的慢性淋巴细胞白血病 (CLL) 十年的疗效

Itsara, Andy; Rogness, Victoria M; Samples, Laura; Yuan, Constance M; Wang, Hao-Wei; Ahn, Inhye E; Farooqui, Mohammed Z H; Tian, Xin; Sun, Clare; Tomasulo, Emily; Soto, Susan; Superata, Jeanine; Bezkorovaynaya, Larisa; Hughes, Thomas E; Nierman, Pia; Wiestner, Adrian

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells

通过靶向共价沉积在淋巴瘤细胞上的补体C3片段来增强CD20单克隆抗体疗法的疗效

Baskar, Sivasubramanian; Peng, Haiyong; Gaglione, Erika M; Carstens, Elizabeth J; Lindorfer, Margaret A; Ahn, Inhye E; Herman, Sarah E M; Skarzynski, Martin; Chang, Jing; Keyvanfar, Keyvan; Butera, Vicent; Blackburn, Amy; Vire, Bérengère; Maric, Irina; Stetler-Stevenson, Maryalice; Yuan, Constance M; Eckhaus, Michael A; Soto, Susan; Farooqui, Mohammed Z H; Taylor, Ronald P; Rader, Christoph; Wiestner, Adrian

Reduction of Fusarium head blight and trichothecene contamination in transgenic wheat expressing Fusarium graminearum trichothecene 3- O-acetyltransferase

表达禾谷镰刀菌单端孢霉烯 3- O-乙酰转移酶的转基因小麦中镰刀菌赤霉病和单端孢霉烯污染的减少

Gabdiel Yulfo-Soto, Susan McCormick, Hui Chen, Guihua Bai, Harold N Trick, Guixia Hao

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

CD49d表达可识别出一种生物学上独特的慢性淋巴细胞白血病亚型,该亚型在接受BTK抑制剂治疗后无进展生存期较差。

Alsadhan, Anfal; Chen, Jonathan; Gaglione, Erika M; Underbayev, Chingiz; Tuma, Pamela L; Tian, Xin; Freeman, Lita A; Baskar, Sivasubramanian; Nierman, Pia; Soto, Susan; Itsara, Andy; Ahn, Inhye E; Sun, Clare; Bibikova, Elena; Hartmann, Tanja Nicole; Mhibik, Maissa; Wiestner, Adrian

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model

伊布替尼治疗慢性淋巴细胞白血病患者预后预测:四因素预后模型的建立与验证

Ahn, Inhye E; Tian, Xin; Ipe, David; Cheng, Mei; Albitar, Maher; Tsao, L Claire; Zhang, Lei; Ma, Wanlong; Herman, Sarah E M; Gaglione, Erika M; Soto, Susan; Dean, James P; Wiestner, Adrian

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

布鲁顿酪氨酸激酶抑制剂对佐剂重组乙型肝炎疫苗和带状疱疹疫苗疗效的影响

Pleyer, Christopher; Ali, Mir A; Cohen, Jeffrey I; Tian, Xin; Soto, Susan; Ahn, Inhye E; Gaglione, Erika M; Nierman, Pia; Marti, Gerald E; Hesdorffer, Charles; Lotter, Jennifer; Superata, Jeanine; Wiestner, Adrian; Sun, Clare

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study

风险适应性、基于奥法妥木单抗的化疗免疫疗法和巩固疗法治疗初治慢性淋巴细胞白血病:一项 II 期研究

Desai, Sanjal; Mo, Clifton; Gaglione, Erika M; Yuan, Constance M; Stetler-Stevenson, Maryalice; Tian, Xin; Maric, Irina; Wake, Laura; Farooqui, Mohammed Z; Drinkwater, Dennis C; Soto, Susan; Valdez, Janet; Hughes, Thomas E; Nierman, Pia; Lotter, Jennifer; Marti, Gerald E; Pleyer, Christopher; Sun, Clare; Superata, Jeanine; Nichols, Cydney; Herman, Sarah E M; Lindorfer, Margaret A; Taylor, Ronald P; Wiestner, Adrian; Ahn, Inhye E

A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia

一项针对既往未接受治疗的慢性淋巴细胞白血病患者的伊布替尼联合短期氟达拉滨治疗的II期研究

Pleyer, Christopher; Tian, Xin; Rampertaap, Shakuntala; Mu, Rui; Soto, Susan; Superata, Jeanine; Gaglione, Erika; Sun, Clare; Lotter, Jennifer; Stetler-Stevenson, Maryalice; Yuan, Constance M; Maric, Irina; Pittaluga, Stefania; Rosenzweig, Sergio; Fleisher, Thomas; Wiestner, Adrian; Ahn, Inhye E

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors

布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病患者可重建体液免疫并降低感染风险

Pleyer, Christopher; Sun, Clare; Desai, Sanjal; Ahn, Inhye E; Tian, Xin; Nierman, Pia; Soto, Susan; Superata, Jeanine; Valdez, Janet; Lotter, Jennifer; Wiestner, Adrian

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

慢性淋巴细胞白血病患者对伊布替尼的反应深度和持久性:一项 II 期研究的 5 年随访结果

Ahn, Inhye E; Farooqui, Mohammed Z H; Tian, Xin; Valdez, Janet; Sun, Clare; Soto, Susan; Lotter, Jennifer; Housel, Stephanie; Stetler-Stevenson, Maryalice; Yuan, Constance M; Maric, Irina; Calvo, Katherine R; Nierman, Pia; Hughes, Thomas E; Saba, Nakhle S; Marti, Gerald E; Pittaluga, Stefania; Herman, Sarah E M; Niemann, Carsten U; Pedersen, Lone B; Geisler, Christian H; Childs, Richard; Aue, Georg; Wiestner, Adrian